In clinical trials, strict protocols ensure patients receive treatments exactly on schedule. In the real world, however, chronic conditions requiring frequent, invasive interventions suffer from a steep drop-off in compliance. This "efficacy-effectiveness gap" is particularly acute in diseases managed via repeated injections, where patient fatigue and logistical hurdles lead to missed appointments and disease progression.
To bridge this gap, a major paradigm shift is underway across pharmacology: engineering therapies not just for higher potency, but for greater durability to safely extend the interval between treatments.
The Kinetics of High-Dose Clearance
One of the most direct ways to extend a drug's therapeutic window is to increase its initial concentration, exploiting the mathematics of first-order elimination kinetics. For many biologics, the rate of clearance from a target tissue is proportional to the amount of drug present. By delivering a significantly higher initial dose, the time required for the drug concentration to decay below its minimum effective threshold is lengthened.
This principle is clearly illustrated by recent advancements in treating retinal vascular diseases. In Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial, Suzuma et al. demonstrated that increasing the dose of intravitreal aflibercept from the standard 2 mg to 8 mg allowed the treatment interval for diabetic macular edema (DME) to be extended up to 16 weeks—double the standard 8-week regimen—while maintaining equivalent visual and anatomical outcomes.
To understand the structural impact of this high-dose switch, Hafner et al. leveraged deep-learning semantic segmentation in Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration to show that the 8 mg formulation successfully suppresses persistent disease biomarkers, such as intraretinal fluid, in therapy-resistant patients. Real-world evidence from Liesenhoff et al. in High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent? confirms that clinicians are actively utilizing this high-dose variant as a "switch" therapy specifically to alleviate the injection frequency of patients struggling under standard regimens.
Furthermore, optimizing the initial dosing schedule itself can yield long-term durability benefits; Liu et al. found in Study on the efficacy of different injection regimens of aflibercept in the treatment of diabetic macular edema that a denser initial loading phase (five injections versus three) stabilizes retinal anatomy more effectively, ultimately reducing the frequency of subsequent "as-needed" interventions.
Dual-Pathway Inhibition to Prevent Escape Mechanisms
While increasing the dose extends the clearance timeline of a single drug, biological systems often bypass single-target interventions through redundant signaling pathways. For instance, blocking vascular endothelial growth factor (VEGF) can cause tissues to upregulate alternative angiogenic pathways, such as Angiopoietin-2 (Ang-2), leading to a rapid return of fluid and requiring frequent re-injection.
To block these escape mechanisms, researchers design bispecific molecules that neutralize multiple pathways simultaneously, stabilizing tissue architecture for much longer periods. Eckardt et al. in Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration and Lorger in Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration – 6 month results after completion of the loading phase demonstrated that switching patients with recalcitrant neovascular age-related macular degeneration (nAMD) to faricimab—a bispecific antibody targeting both VEGF-A and Ang-2—extends the time between treatments by over 50% while maintaining stable visual acuity.
Similarly, Lu et al. in Safety and Efficacy of Multiple Escalating Doses of RC28-E for Neovascular Age-Related Macular Degeneration: A Phase 1b Trial showed that RC28-E, a bispecific fusion protein targeting both VEGF and fibroblast growth factor (FGF), safely achieves sustained anatomical improvements over 48 weeks, offering another avenue for reducing dosing frequency.
When single bispecific molecules are not used, combining distinct therapeutic modalities can achieve a similar stabilizing effect. In Combination pharmacotherapy for macular edema associated with retinal vein occlusion, the authors reviewed how combining anti-VEGF agents with corticosteroids provides a more comprehensive, durable response in macular edema, while Li et al. in Intravitreal ranibizumab injection combined with photodynamic therapy for polypoidal choroidal vasculopathy demonstrated that pairing an anti-VEGF injection with photodynamic laser therapy at a precise 7-day interval nearly halves the number of follow-up injections required.
Molecular Engineering for Systemic Longevity
Outside of localized compartments like the eye, systemic therapies face rapid degradation by circulating enzymes and filtration by the kidneys. Extending administration intervals from a daily or monthly cadence to a weekly or semi-annual schedule requires engineering the molecules to evade clearance or embedding them within slow-release matrices.
In supportive cancer care, for example, standard granulocyte colony-stimulating factors (G-CSF) require daily injections to manage neutropenia. To eliminate this daily burden, Ji et al. evaluated efbemalenograstim alfa in Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial. This molecule utilizes an Fc-fusion protein design that binds to neonatal Fc receptors (FcRn), exploiting the body's natural IgG recycling mechanism to protect the protein from intracellular destruction and significantly extend its half-life.
Similarly, in managing post-transplantation thrombocytopenia, Ding et al. showed in Romiplostim versus Recombinant human thrombopoietin in umbilical cord blood transplantation: a single-center retrospective study that the weekly thrombopoietin mimetic romiplostim offers a highly effective, lower-labor alternative to daily recombinant human thrombopoietin injections.
For long-term hormone suppression in prostate cancer, physical encapsulation provides an alternative solution: Yee et al. demonstrated in A 6-month sustained-release formulation of triptorelin for locally advanced or metastatic prostate cancer: a real-world experience in Asia that a 6-month sustained-release depot formulation of triptorelin maintains testosterone suppression with a 92% real-world adherence rate, replacing highly disruptive monthly or quarterly clinical visits with a twice-a-year injection.
Permanent and Sustained Delivery Horizons
The logical conclusion of extending treatment intervals is the transition from temporary maintenance to permanent, localized production. By utilizing advanced delivery vehicles and genetic editing, researchers aim to shift the therapeutic burden entirely away from the patient.
Li et al. highlighted in Nanotechnology for Age-Related Macular Degeneration how nanotechnology-based drug delivery systems can protect therapeutic payloads and provide controlled, long-term release directly within target tissues, bypassing the limitations of frequent manual administration.
Taking this a step further, Hu et al. demonstrated in Nme2Cas9‐mediated therapeutic editing in inhibiting angiogenesis after wet age‐related macular degeneration onset that a single administration of an adeno-associated virus (AAV) vector carrying the Nme2Cas9 gene-editing system can permanently disrupt angiogenic pathways in vivo. By rewriting the genetic drivers of abnormal blood vessel growth, this approach offers a one-time intervention that could completely eliminate the need for ongoing maintenance therapy.
Concurrently, exploring alternative biological pathways, such as the anti-inflammatory and antioxidant properties of ghrelin investigated by Bai et al. in Ghrelin Ameliorates Diabetic Retinal Injury: Potential Therapeutic Avenues for Diabetic Retinopathy, aims to discover more sustainable, disease-modifying mechanisms that prevent the rapid recurrence typical of current transient therapies.
Key Foundational Work
Intravitreal ranibizumab injection combined with photodynamic therapy for polypoidal choroidal vasculopathy (2017) — contributed 1 concept elements to this direction.
Combination pharmacotherapy for macular edema associated with retinal vein occlusion (2019) — contributed 1 concept elements to this direction.